THE PLACE OF METABYOTICS IN PREVENTION AND TREATMENT OF ANTIBIOTIC-ASSOCIATED DIARRHEA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

To date, there are many cases of irrational use of antibacterial drugs (ABDs): prescription without indications, «just in case», violation of schemes of their use, a broad assignment of reserve ABDs. Antibiotic-associated diarrhea is one of the significant side effects associated with the therapy with ABDs. To date, one of the most promising areas in the therapeutic correction of microbiocenosis disorders is metabiotic therapy.

Texto integral

Acesso é fechado

Sobre autores

A. Ploskireva

FBIS CSRI of Epidemiology of Rospotrebnadzor

Email: antonina@ploskireva.com
Associate Professor, Senior Researcher Moscow

A. Gorelov

SBHCI «Infectious Clinical Hospital № 2» of the Moscow Healthcare Department

Moscow

L. Golden

SBHCI «Infectious Clinical Hospital № 2» of the Moscow Healthcare Department

Moscow

Bibliografia

  1. Alali F.Q., Li C., Oberlies N.H. Proliferation of antibiotic-producing bacteria and concomitant Future. Front. Microbiol. 2010;1:134.
  2. Falkinham J.O., Wall I.E., Tanner J.R., Tawaha K., antibiotic production as the basis for the antibiotic activity of Jordan's red soils. Appl. Environ Microbiol. 2009;75(9):2735-41.
  3. Nelson M.L., Dinardo A., Hochberg J., Armelagos G.J. Brief communication: mass spectroscopic characterization of tetracycline in the skeletal remains of an ancient population from Sudanese Nubia 350-550 CE. Am. J. Phys. Anthropol. 2010;143(1):151-54.
  4. Горелов А.В., Усенко Д.В. Современные подходы к профилактике антибиотикоассоциированной диареи у детей. Consilium Medicum. Педиатрия. Прил. 2005;2.
  5. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. 1998;16:292-307.
  6. Wiström J., Norrby S.R., Myhre E.B., Eriksson S., Granström G., Lagergren L., Englund G., Nord C.E., Svenungsson B. Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study. Antimicrob. Chemother. 2001;47:43-50.
  7. Elstner C.L., Lindsay A.N., Book L.S., Matsen J.M. Lack of relationship of Clostridium difficile to antibiotic-associated diarrhoea in children. Pediatr. Inf. Dis. 1983;2:364-66.
  8. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., Lacombe A., Rembert F., Toursel F., Bernasconi P., Gottrand F., McFarland L.V., Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J. Pediatr. Gastroenterol. Nutr. 2003;37:22-6.
  9. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 2005; 21:583-90.
  10. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные представления об инфекции Clostridium difficile. Клин. микробиол. и антимикроб. химиотер. 2002;4(3): 200-32.
  11. Плоскирева А.А., Горелов А.В. Системный подход к оценке микробиоценоза желудочно-кишечного тракта при острых кишечных инфекциях у детей. Совр. проблемы науки и образования. 2015;5. URL: http://www.science-education.ru/ru/ article/view?id=22040 (дата обращения: 17.04.2016).
  12. Beaugerie L., Beaugerie L., Petit J.C. Microbialgut interactions in health and disease. Antibiotic-associated diarrhea. Best. Pract. Res. Clin. Gastroenterol. 2004;18:337-52.
  13. Clausen M.R., Bonnen H., Tvede M., Mortensen P.B. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterol. 1991;101: 1497-504.
  14. Asha N.J. Tompkins D., Wlilcox M.H. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J. Clin. Microbiol. 2006;44:2785-91.
  15. Ardawi M.S.M., Newsholme E.A. Fuel utilization in colonocytes of the rat. Biochem. J. 1985;231:713-19.
  16. Hogenauer C., Langner C., Beubler E. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N. Engl. J. Med. 2006;355:2418-26.
  17. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin. Infect. Dis. 1998;27:702-10.
  18. Thomas M.R., Litin S.C., Osmon D.R., Corr A.P., Weaver A.L., Lohse C.M. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin. Proc. 2001;76:883-89.
  19. Ивашкин В.Т., Шептулин А.А. Синдром диареи. М., 2000;135 с.
  20. Каннер Е.В., Горелов А.В., Крутихина С.Б. Антибиотико-ассоциированная диарея у детей: современный взгляд на проблему. Мед. совет. 2017;1:226-30.
  21. Floch M.H. Recommendations for Probiotic Use in Humans-A 2014 Update. Pharmaceuticals (Basel). 2014;7(10):999-1007. Published online 2014 Oct 10.
  22. Lau C.S., Chamberlain R.S. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int. J. Gen. Med. 2016; 9:27-37.
  23. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Br. Med. J. 2002; 324:1361-64.
  24. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 2002;16:1461-67.
  25. Szajewska H., Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment. Pharmacol. Ther. 2005;22:365-72.
  26. Hawrelak J.A., Whitten D.L., Myers S.P Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 2005;72:51-6.
  27. Shenderov B.A. Probiotic (symbiotic) bacterial languages. Anaerobe. 2011;17(6):490-95.
  28. Сафонова М.А., Кузнецов О.Ю. Пробиотические препараты для коррекции микроэкологических нарушений кишечника. Вестн. Ивановской мед. акад. 2012; 17(1):49-54.
  29. Ардатская М.Д. Клиническое значение короткоцепочечных жирных кислот при патологии желудочно-кишечного тракта. Дисc. докт. мед. наук. М., 2003.
  30. Головенко О.В., Халиф И.Л., Головенко А.О. Роль масляной кислоты в лечении органических и функциональных заболеваний толстой кишки. Клин. перспективы гастроэнтерол., гепатол. 2001;3:20-9.
  31. Mischke M., Plösch T. The Gut Microbiota and their Metabolites: Potential Implications for the Host Epigenome. Adv. Exp. Med. Biol. 2016;902:33-44.
  32. Akbari E., Asemi Z., Daneshvar Kakhaki R., Bahmani F., Kouchaki E., Tamtaji O.R., Hamidi G.A., Salami M. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Front. Aging. Neurosci. 201610;8:256.
  33. Mrasek M., Fidler A. Access to pharmaceuticals and regulation in the Commonwealth of Independent States. In: Mossialos E., Mrasek M., Walley T., ed. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity adn Quality. Maidenhead, Berkshire: Open UP; 2004. 341 p.
  34. Hood K., Nuttall J., Gillespie D., Shepherd V., Wood F., Duncan D., et al. Probiotics for Antibiotic-Associated Diarrhoea (PAAD): a prospective observational study of antibiotic-associated diarrhoea (including Clostridium difficile-associated diarrhoea) in care homes. Health Technology Assessment. 2014;18(Issue:63).
  35. Antunes L.C., Han J., Ferreira R.B., Lolic P., Borchers C.H., Finlay B.B. Effect of Antibiotic Treatment on the Intestinal Metabolome. Antimicrob Agents Chemother. 2011;55(4):1494-503. Published online 2011 Jan 31.
  36. Несчисляев В.А., Крылова Т.В., Чистохина Л.П. Исследование специфической активности комплексного метаболитного пробиотика. Биопрепараты. Профилактика. Диагностика. Лечение. 2013;2(46):32-34.
  37. Погорелова О.О., Горелов А.В., Усенко Д.В., Плоскирева А.А. Опыт применения метаболического пробиотика в лечении острых респираторных заболеваний у детей. Вопросы практической педиатрии. 2015;10(4):61-65.
  38. Плоскирева А.А., Горелов А.В. Место метаболитных пробиотиков в практике клинициста. Педиатрия. Журнал им. Г.Н. Сперанского. 2014;3:232.
  39. Чичерин И.Ю., Погорельский И.П., Лундовских И.А., Дармов И.В., Гаврилов К.Е., Позолотина Н.В. Эволюция пробиоти ков: историческая оценка и перспектива. Дневник казанской медицинской школы. 2015;1(7):42-51
  40. Инструкция по медицинскому применению препарата Хилак форте.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies